Hematologic Malignancy
Follicular Helper T-Cell Lymphoma
CI-CAN-00007714Explore in graph →
Hematologic17 active trials
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00007714Explore in graph →
Clinical trials
126 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (24)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06561048 | Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma | recruiting | Phase 3 | 150 | Corvus Pharmaceuticals, Inc.INDUSTRY | 3 | Sep 25, 2026 | clinicaltrials |
| NCT06137144 | AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.(PRIMAVERA) | recruiting | Phase 1 / Phase 2 | 161 | AstraZenecaINDUSTRY |
| 11 |
| Sep 14, 2026 |
| clinicaltrials |
| NCT06724237 | Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy | recruiting | Phase 3 | 294 | Eastern Cooperative Oncology GroupNETWORK | 2 | Sep 14, 2026 | clinicaltrials |
| NCT06393738 | A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma. | recruiting | Phase 1 | 329 | Arvinas Inc.INDUSTRY | 5 | Sep 4, 2026 | clinicaltrials |
| NCT04803201 | Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma | recruiting | Phase 2 | 170 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT03113500 | Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma | active not recruiting | Phase 2 | 48 | City of Hope Medical CenterOTHER | 2 | Aug 21, 2026 | clinicaltrials |
| NCT07293403 | Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas | recruiting | Phase 2 | 25 | City of Hope Medical CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07691450 | Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma | not yet recruiting | Phase 1 | 40 | City of Hope Medical CenterOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT02520791 | Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma | active not recruiting | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 2 | Jun 26, 2026 | clinicaltrials |
| NCT01787409 | Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency | active not recruiting | N/A | 565 | Mayo ClinicOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07278856 | Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas | recruiting | Phase 1 | 20 | City of Hope Medical CenterOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT03598998 | Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas | active not recruiting | Phase 1 / Phase 2 | 13 | City of Hope Medical CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT05978141 | A Registry for People With T-cell Lymphoma | recruiting | — | 1,000 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT01199562 | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant | active not recruiting | — | 153 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT03278782 | Study of Pembrolizumab (MK-3475) in Combination With Romidepsin | active not recruiting | Phase 1 / Phase 2 | 39 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT04234048 | Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma | recruiting | Phase 1 | 46 | SciTech Development, Inc.INDUSTRY | 1 | Sep 22, 2025 | clinicaltrials |
| NCT07046182 | Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of. Angioimmunoblastoma Foresight | active not recruiting | Phase 4 | 34 | Zhengzhou UniversityOTHER | 1 | Jul 1, 2025 | clinicaltrials |
Data updated 5 days agoSource updated Sep 25, 2026source: clinicaltrials